Jazz Pharmaceuticals (JAZZ) Q1 FY26 earnings call

Jazz Pharmaceuticals delivered an exceptionally strong first quarter, marked by record revenues and double-digit growth across its key commercial brands. The company is actively preparing for the potential launch of zanidatamab in HER2-positive GEA following its FDA Priority Review, while also advancing its broader pipeline. With a robust financial position, Jazz remains focused on strategic business development to expand its rare disease portfolio and leverage its existing capabilities.